BridgingStudiesAGenomicApproach專題培訓課件_第1頁
BridgingStudiesAGenomicApproach專題培訓課件_第2頁
BridgingStudiesAGenomicApproach專題培訓課件_第3頁
BridgingStudiesAGenomicApproach專題培訓課件_第4頁
BridgingStudiesAGenomicApproach專題培訓課件_第5頁
已閱讀5頁,還剩58頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領

文檔簡介

2023/10/101BridgingStudies-AGenomicApproach

atThe34TrainingCourseonClinicalTrialsFoundationofMedicalProfessionalsAllianceinTaiwan

October14,2023TheviewsexpressedinthispaperareprofessionalopinionsofthepresenterandmaynotnecessarilyrepresentthepositionoftheNationalTaiwanUniversityandNationalHealthResearchInstitutes,Taiwan.2023/10/102AcknowledgementsandThanks

Herng-DerChen,MD,PhD,CenterforDrugEvaluation

MeyWang,PhD,CenterforDrugEvaluationChin-FuHsiao,PhD,NationalHealthResearchInstitutes2023/10/103OutlineI.StatisticalInterpretationofICHE5II.ImplementationofBridgingStudiesIII.ExamplesofBridgingStudiesIV.CurrentStatisticalApproachesV.AStatisticalGenomicApproachVI.Summary2023/10/104StatisticalInterpretationofICHE5ICHE5

ICHHarmonisedTripartiteGuideline(Feb.5,1998)EthnicFactorsintheAcceptabilityofForeignClinicalData

AUSFDAGuidance(FederalRegister,June10,1998)2023/10/105StatisticalInterpretationofICHE5ICHE5EthnicFactorsintheAcceptabilityofForeignClinicalDataThepurposeofthisguidanceistofacilitatetheregistrationofmedicinesamongICHregionsbyrecommendingaframeworkforevaluatingtheimpactofethnicfactorsuponamedicine’seffect,i.e.,itsefficacyandsafetyataparticulardosageanddoseregimen.2023/10/106StatisticalInterpretationofICHE5ObjectivesofICHE5(Section1.1)Todescribethecharacteristicsofforeignclinicaldatathatwillfacilitatetheirextrapolationtodifferentpopulationandsupporttheiracceptanceasabasisforregistrationofamedicineinanewregion.Todescriberegulatorystrategiesthatminimizeduplicationofclinicaldataandfacilitateacceptanceofforeignclinicaldatainthenewregion. Todescribetheuseofbridgingstudy,whennecessary,toallowextrapolationofforeignclinicaldatatoanewregion.Todescribedevelopmentstrategiescapableofcharacterizingethnicfactorinfluencesonsafety,efficacyanddoseregion2023/10/107StatisticalInterpretationofICHE5ICHE5EthnicFactorsintheAcceptabilityofForeignDataBRIDGINGDATAPACKAGE(Section3.2)

Abridgingdatapackageconsistsof 1)selectedinformationfromtheCompleteDataClinicalPackage

thatisrelevanttothepopulationofthenewregion,including pharmacokineticdata,andanypreliminarypharmacodynamic anddose-responsedata,

and 2)ifneeded,abridgingstudytoextrapolatetheforeignefficacy

and/orsafetydatatothenewregion.2023/10/108StatisticalInterpretationofICHE5CompleteClinicalDataPackage(CCDP)

Aclinicaldatapackageintendedforregistrationcontainingclinicaldatathatfulfillsregulatoryrequirementsofthenewregionandpharmacokineticdatarelevanttothepopulationinthenewregion

2023/10/109StatisticalInterpretationofICHE5BridgingStudy

Abridgingstudyisdefinedasastudyperformedinthenewregiontoprovidepharmacodynamicorclinicaldataonefficacy,safety,dosageanddoseregimeninthenewregionthatwillallowextrapolationoftheforeignclinicaldatatothepopulationinthenewregion2023/10/1010

ExtrapolationandSimilarity

ICHE5EthnicFactorsintheAcceptabilityofForeignDataIfthebridgingstudyshowsthatdoseresponse,safetyandefficacyinthenewregionaresimilar,thenthestudyisreadilyinterpretedascapableof"bridging"theforeigndataIfabridgingstudy,properlyexecuted,indicatesthatadifferentdoseinthenewregionresultsinasafetyandefficacyprofilethatisnotsubstantiallydifferent

fromthatderivedintheoriginalregion,itwilloftenbepossibletoextrapolatetheforeigndatatothenewregion,withappropriatedoseadjustment,ifthiscanbeadequatelyjustified(e.g.,bypharmacokineticand/orpharmacodynamicdata).2023/10/1011EthnicFactors

IntrinsicEthnicFactors

aremoregeneticandphysiologicinnature e.g.,geneticpolymorphism,age,gender,height,weight,leanbodymass,bodycomposition,anddiseaseconditions,etc.ExtrinsicEthnicFactors

aremoresocialandculturalinnature e.g.,environment,culture,medicalpractice,healthinsurance,practicesinclinicaltrialsorconduct2023/10/1012Anapprovedreportofalocalclinicaltrialstudy

is

requiredforthenewdrugapplicationinTaiwan—July7.1993:Double7AnnouncementDisadvantages:

Aminimalsamplesizeof40asrequiredcouldbe

difficulttoprovideconclusiveandsubstantialevidenceofefficacyandsafetyThestudydesignofthelocaltrialusuallyonly

repeatedastudythathasbeendoneintheforeigncountriesbutinasmallersamplesize;ThestudyhasnotbeendesignedbasedonthemedicalsituationinTaiwan

Taiwan’sStrategytoImplementBridgingStudy2023/10/1013Taiwan’sStrategytoImplementBridgingStudySmoothlyconvertcompulsoryLocalClinicalTrials(LCT)tomeaningfulbridgingstudiesGradually,stepwiseannouncewaivedlocalclinicaltrialsCreateanenvironment:(1)meetinternationalregulations,ICH(2)requireoptimizeddosageforTaiwanesepatientsCommunicatewithlocalandinternationalpharmaceuticalindustryAnnouncenewregulationsaccordingtotheinternationalnormandtheconsensusfromcommunicationsCreateaninternationalplatform“APEC–Taipei”ImplementDoubleTwelveAnnouncement–BridgingStudy

2023/10/1014StepwiseImplementationTwoyearsafterthe1998announcement,switchfromLCTtobridgingstudyManycommunicationsandnegotiationswithlocalandinternationalpharmaceuticalindustryDec.12,

2023:(DoubleTwelveAnnouncement)–publicannouncementofthebridgingstudyregulations1998:FiveannouncementsofLCTwavierAtwo-yeartransitionperiod:bothLCTandbridgingstudiesconcurrentlyacceptablefrom2023~2023ManyinternationalconferencesheldinTaipeiandotherAsiancountries,regardingBS,throughtheAPECplatformConsultwithCDEtocompletethepracticalissuesrelatedtoimplementationofBSJan.1,

2023:Bridgingevaluation

2023/10/1015

ProductsRequiringNoVerificationofEthnicInsensitivity

DrugsfortreatmentofAIDSDrugsfororgantransplantationTopicalagentsNutritionsupplementsCatharticspriortosurgeryRadio-labelleddiagnosticpharmaceuticalsThedrugistheonlychoiceoftreatmentforagivensevere

diseaseDrugsforlife-threateningdiseasehavedemonstratedabreakthroughefficacyLackingadequatetrialsubjectsforanydrugusedforraredisease2023/10/1016ProductsRequiringVerificationofEthnicInsensitivityAnticancerdrugsDrugswithbreakthroughefficacyDrugsofsingleuseDrugswithdifferentsaltofthesamecompositionandthesameadministeredroutehavebeenapprovedinternalDrugsforchronicpsychologicalorimmunologicaldiseasesandconductingclinicaltrailsinternaldifficultlyEachcompoundsofnewcombinationdrughavebeenprovedinternal,andtheefficacyisthesameasthesinglecompoundDrugswiththemechanism,administeredroute,efficacyandadverseeffect,similartotheapproveddrugsNewcombinationcomposedofsinglecompoundofapprovedcombinationorcompoundsofapprovedcombinationhasthesameefficacyasapprovedcombination2023/10/1017BridgingDataPackageSummaryfortheConsiderationofBridgingStudyAcceptsubmissionCheckingListTechnicalReview(Designatereviewer)ReviewmeetingSponsormeetingSupplementClinicalReviewCommitteeReviewreportandRecommendation:1.NoBridgingstudyrequired2.Bridgingstudyisrequired–TypeofBridgingstudyResultofEvaluation:1.NoBridgingstudyrequired2.Bridgingstudyisrequired–TypeofBridgingstudyNotificationSponsorBoPACDECDEacceptanceverificationExpertConsultants(Statistical,Clinical,Pharmacokineticsreviewers)ScheduleSponsormeetingEvaluationProcess2023/10/10182023/10/10192023/10/1020

ExamplesExampleIDrugAisafixedcombinationoftwoanti-plateletagentswithindicationforsecondarypreventionofthromboembolicstrokeAfterthestandardprocessofBSE,wedecidedtorequestabridgingstudyduetoanethnicdifferenceinmedicalpractice(muchlowerdoseforoneofthecomponentsinTaiwan)andhigherheadache-associateddropoutrateinpreviousPhilippinestudy2023/10/1021Examples

CaseIFixedcombination200mgdipyridamole/25mgaspirin1bidforpreventionofrecurrentstrokeHeadachedropoutrate:Phillipino>CaucasianLocalBridgingStudyResult:first4weeks

ReducedDose2wkFullDose

PlaceboFullDose2wk4wk

Headache8.7%6.7%16.3%

RiskManagement:Changelabeling’sinstructionforuse2023/10/1022ExamplesCaseIIDrugBisanewpotentlipid-loweringagentThePKstudyinJapaneseshowsthatCmaxofJapaneseis1.9~2.5timesofthatforCaucasianwhileAUCis2~2.5timesofthatforCaucasianAlthoughthemeaninterracialdifferenceisnotsubstantial,Taiwanapprovedthedrugwithreducedmaximaldosageduetothedose-dependent,drug-relatedrareSAEofrhabdomyolysis2023/10/1023Examples

CaseIIThedecisionwasfurtherechoedbyUSFDAAfterreviewingtheresultsofaPhaseIVPKstudyinAsian-Americans,FDAurgedthephysicianstoreducethestartingdoseandprescribehighdosewithcautionforAsiansinLabelinginMarch,20232023/10/1024CurrentStatisticalApproaches

“Similarity”

PositiveRxeffectEquivalenceNon-inferiority2023/10/1025ExtrapolationandSimilarityPositivetreatmenteffect(betterthancontrol)

Theefficacyorsafetyofthetestdrugisbetterthancontrolinthenewregion Ho:NT-NC

0vs.Ha:NT-NC>0CurrentStatisticalApproaches2023/10/1026

CurrentStatisticalApproaches

PositiveRxEffect

0

NDOD

2023/10/1027

CurrentStatisticalApproaches

Similarity(Nosubstantialdifference)

Two-sidedequivalence

Therelativeefficacyorsafety(test-control)ofthenewregioniswithinsomeclinicallyacceptancelimitofthatoftheoriginalregion

Let=(NT-NC)-(OT-OC)

Ho:

-or

vs. Ha:-<<

whereissomeclinicallyacceptablelimit(equivalencelimit).

2023/10/1028

CurrentStatisticalApproaches

Equivalence

0

NDOD

2023/10/1029

CurrentStatisticalApproaches

Similarity(Nosubstantialdifference)

One-sidednon-inferiority

Therelativeefficacyorsafety(test-control)ofthenewregionisnotinferiortotheoriginalregionbysomeclinicallyacceptancelimit.

Ho:

-vs.Ha:>-.2023/10/1030

CurrentStatisticalApproaches

Non-inferiority

0

NDOD

2023/10/1031

CurrentStatisticalApproaches

Between-studyAnalysis:Equivalenceornon-inferiority

HierarchicalModel(Liu,Hsueh,andChen2023,BiometricalJ.)

Step1:Fromthecompleteclinicaldatapackage,underthe hierarchicalmodel,usetheclinicaldatafromtheoriginalregionto obtaintheestimateofrelativeefficacyanditsestimatedstandard error. Step2:Fromthedataofthebridgingstudy,obtaintheestimateof relativeefficacyanditsestimatedstandarderrorinthenewregion. Step3:Basedontheestimatedrelativeefficacyanditsstandard errorfromboththenewandoriginalregionsandequivalencelimit ,performtheusualtwoone-sidedtestsprocedureorone-sided non-inferioritytestprocedure(orconfidenceinterval).2023/10/1032EmpiricalBayesianApproach

Bridgingstudies

Smallsamplesize

Needtoborrow“strength”fromCCDPoforiginalregion.

Informationondoseresponse,efficacyandsafetyofthe originalregioncanandshouldbeincorporatedina statisticallysoundmannertoevaluatebridgingevidencebythebridgingstudiesinthenewregion.

Positivetreatmenteffect:(Liu,Hsiao,andHsueh,2023,JBS)

Noninferiorityapproach:(Liu,Hsueh,andHsiao2023,JBS)CurrentStatisticalApproaches2023/10/1033

Between-studyAnalysis:BayesianApproach(Liu,Hsiao,andHsueh,2023)

UsetheestimateoftreatmenteffectfromtheoriginalregionformulatedasanormalpriorComputetheposteriortreatmenteffectwiththedatafromthenewregionComputetheposteriorprobabilityofsimilarity,Pspastheposteriorprobabilityofapositivetreatmenteffect

Concludetheresultsoftheforeignregioncanbeextrapolatedtothenewregionif

Pspis

sufficientlylarge.

SamplesizemightbedeterminedbasedonthedifferencebetweentheposteriorandpriortreatmenteffectCurrentStatisticalApproaches2023/10/1034

CurrentStatisticalApproaches ForapositivetreatmenteffectThemodel(Liu,Hsiao,andHsueh,2023)Yi=P(1-Xi)+{Nzi+O(1-Zi)}Xi+i,I~N(0,2),where

P:controleffectN:treatmenteffectofthenewregionO:treatmenteffectoftheoriginalregionX=1(0)treatment(control)groupZ=1(0)new(originalregion)2023/10/1035CurrentStatisticalApproachesForapositivetreatmenteffectEmpiricalBayesianApproach

(Liu,Hsiao,andHsueh,2023)GivenP,N,theestimatesofP,N,saypandaNfollowsabivariatenormaldistributionwithmeanvector(P,N)’andthediagonalcovariancematrixdiag(VP,VN).Inaddition,thepriordistributionof(P,N,O)’followsatrivariatenormaldistributionwithmeanvector(p,N,O)anddiagonalcovariancematrixdiag(2p,2N,2O).Concludeapositivetreatmenteffectifposteriorprobabilityofsimilarity

P(N-P>0dataandprior)>1-,forsome>0.5.(Simon,1999)

2023/10/1036CurrentStatisticalApproachesForapositivetreatmenteffectEmpiricalBayesianApproach

(Liu,Hsiao,Hsueh,2023)UnderassumptionthatN=O,forP(N-P>0dataandprior)>1-,thefollowingequationmustbesatisfied (O-p)/2O+2p

=-1(1-q),where-1(1-q)representstheevidenceforpositivetreatmenteffectintheoriginalregion. 2023/10/1037

CurrentStatisticalApproaches

ResultsfromOriginalRegionChangefrombaselineinsittingDBPatweek12

RegionStatistics Test PlaceboI n 138 132 Mean -18 -3 SD 11 12II n 185 179Mean -17 -2 SD 10 11III n 141 143 Mean -15 -5 SD 13 14

2023/10/1038CurrentStatisticalApproaches

ResultsfromNewRegion:ChangefrombaselineinSittingDBPatweek12

RegionStatistics Test PlaceboNew n 64 65 Mean -4.5 -3.8 SD 11 11Posteriorprobabilityofsimilarity:Psp12023/10/1039

CurrentStatisticalApproaches

Originalregion:Efficacyofthetestdrugissuperiortotheplacebo.NewRegion:ReductionofsittingBPofthetestdrugissameasthatoftheplacebo.Conclusion:Theresultsoftheoriginalregioncanbeextrapolatedtothenewregiondespiteofinconsistentresultsbetweenoriginalandnewregions.Evaluationofbridgingstudiesisoverwhelminglybytheresultsoforiginalregionduetoimbalanceofinformationprovidedbythetworegions.

.2023/10/1040

CurrentStatisticalApproaches

AMixturePriorBayesianApproach(Hsiao,HsuandLiu,2023)Define

N=NT-NC

Amixture

priormodel:(N)=1(N)+(1-)2(N)

1(N)isanoninformativepriorandissettobe1.2(N)isanormalpriorthatsummarizestheresultsoforiginalregionisaweighingfactor;01=0:thesamepriorusedinLiu,HsuehandHsiao(2023)=1:noresultsoforiginalregionisused

2023/10/1041

CurrentStatisticalApproaches

PosteriorProbabilityofSimilarity2023/10/1042

CurrentStatisticalApproaches

MarginalDistribution2023/10/1043

CurrentStatisticalApproaches

PosteriorDistribution2023/10/1044

CurrentStatisticalApproaches

FindthesmallestnNthat2023/10/1045

CurrentStatisticalApproaches

GroupSequentialMethod(Hsiao,Xu,Liu,2023)ATwo-stageDesign(Hsiao,Xu,Liu,2023)

Reason: UnderthehierarchicalmodelorBayesianapproach, evaluationofsimilarityornon-inferioritybasedonthe differenceofrelativeefficacymightstillrequirelarge samplesizeforthebridgingstudyinthenewregion. Thesearebetween-studyanalysiswithoutinternalvalidityandmayprovidebiasedinference

Criterionforsimilarity Maintenanceofthesimilartrendinthenewregion2023/10/1046

CurrentStatisticalApproaches

Step1:Whendesigningtheadequateandwell-controlled studiesforsubmissiontotheoriginalregion,includethe patientsinthenewregionaspartofrecruitmentforthe wholestudy(Thebridgingstudyisasub-study).Step2:Thestudyshouldhaveastructureofgroupsequential design.Usetheregionasgroupsequencetoenrollthe patientsfromtheoriginalregionfirstandthentoenroll patientsfromthenewregionsubsequently.Step3:Pre-specifytheboundariesintheprotocol,sayalpha- spendingfunction.Becausetheprimaryobjectiveofthe trialisforsubmissiontotheoriginalregion,mostoftypeI errorrateshouldbespentfortheinterimanalysisbasedon theresultsfromtheoriginalregion.2023/10/1047

CurrentStatisticalApproaches

Step4:Whentherecruitmentofpatientsintheoriginalregionis completed,performtheinterimanalysisuptoresultsofthe originalregion.Step5:Enrollthepatientsinthenewregion.Afterthe recruitmentofthepatientsiscompleted,performthefinal analysiswithadditionaldatafromthenewregionand adjustmentoftheinterimanalysis.Ifsimilarresults(i.e., similarsignificanceleveltomeetrequirementofcrossing boundary)areobtainedforthefinalanalysis,thentheresults ofthenewregioncanbedeclaredsimilaritytotheoriginal region.2023/10/1048TargetedClinicalTrialsHER2(thehumanepidermalgrowthfactorreceptor2)geneinmetastaticbreastcancer-Herceptin-requirementofscreeningthepatientswithover-expressedHER2level(Slamon,2023).Estrogenreceptorpolymorphism-EstrogenReplacementAtherosclerosistrial(ERA,Herrington,etal,2023):atotalof9SNPswereidentifiedandinteractionbetweentreatmentofHRTandsomeofSNPsinelevationoflipidlevelsissuggestedSamplesizedetermination:Fijal,etal.(2023)andMaitournamandSimon(2023).AStatisticalGenomicApproach

2023/10/1049TargetedClinicalTrialsandEGFRIressa(gefitnib)andTarceva(Erlotinib)aretargtedattheEGFRpathway.Efficacyiscorrelatedto race numberofgenecopiesproteinexpressionEGFRmutationGappuzzoetal.(JNCI,2023),Tsao,etal(NEJM,2023)AStatisticalGenomicApproach2023/10/1050AStatisticalGenomicApproachAsian(n=342)

HR=0.66(0.48,0.91),P=.011RR=12.0%Non-Asian(n=1350)

HR=0.93(0.81,1.08),P=.364RR=6.5% 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 151.00.90.80.70.60.50.40.30.20.10.0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15——

IRESSA?------

PlaceboTime,moPatientssurviving(%)2023/10/1051

From:Tsao,etal(2023,NEJM)AStatisticalGenomicApproach2023/10/1052From:Tsao,etal(2023,NEJM)AStatisticalGenomicApproach2023/10/1053From:Tsao,etal(2023,NEJM)AStatisticalGenomicApproach2023/10/1054From:Tsao,etal(2023,NEJM)AStatisticalGenomicApproach2023/10/1055

AStatisticalGenomicApproach

CurrentstatisticalmethodsforbridgingstudiesdonotreallytakeethnicfactorsintoconsiderationsAfterHumanGenomeProject,theavailabilityofgenomicdatacanprovidethenecessaryquantitativeinformationforintrinsicethnicfactorGenomicinformationshouldbeincorporatedintoevaluationofbridgingstudiesBridgingstudiesmaybeconsideredasonetypeoftargetedclinicaltrialswithgenomicdataasthebio-targetsforintrinsicethnicfactors2023/10/1056

AStatisticalGenomicApproach

StratifiedApproach

OriginalRegion Genetic

Polymorphism Proportion Test Control

1 PO1

1T 1C

2 PO2

2T 2C . . . .. . . .

K POK

KT KC

POiiT POiiC

2023/10/1057

AStatisticalGenomicApproach

StratifiedApproach

NewRegion

Genetic

Polymorphism Proportion Test Control

1 PN1

1T 1C

2 PN2

2T 2C . . . .. . . .

K PNK

KT

KC

PNiiT PNiiC

2023/10/1058

AStatisticalGenomicApproachPoi:theproportionoftypeiforsomegeneticpolymorphismintheoriginalregionPNi:theproportionoftypeiforsomegeneticpolymorphisminthenewregioniT:themeanresponseofapatientwithtypeipolymorphismintreatmentgroup2C:themeanresponseofapatientwithtypeipolymorphismincontrolgroupOT=POiiT:themeanresponseofthetreatmentgroupintheoriginalregion(meanofamixturedistribution)OC=POiiC:themeanresponseofthecontrolgroupintheoriginalregionNT=P

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論